7.38
0.34 (4.83%)
| Previous Close | 7.04 |
| Open | 7.00 |
| Volume | 66,303 |
| Avg. Volume (3M) | 747,783 |
| Market Cap | 24,142,046 |
| Price / Sales | 132.61 |
| Price / Book | 0.460 |
| 52 Weeks Range | |
| Earnings Date | 10 Aug 2023 - 14 Aug 2023 |
| Operating Margin (TTM) | -15,202.38% |
| Diluted EPS (TTM) | -0.930 |
| Quarterly Revenue Growth (YOY) | 10.50% |
| Total Debt/Equity (MRQ) | 0.19% |
| Current Ratio (MRQ) | 4.35 |
| Operating Cash Flow (TTM) | -33.97 M |
| Levered Free Cash Flow (TTM) | -17.00 M |
| Return on Assets (TTM) | -33.14% |
| Return on Equity (TTM) | -56.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | VYNE Therapeutics Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 3.0 |
| Average | -0.75 |
|
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.07% |
| % Held by Institutions | 51.02% |
| 52 Weeks Range | ||
| Median | 4.50 (-39.02%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 25 Apr 2025 | 4.50 (-39.02%) | Buy | 1.85 |
| 06 Mar 2025 | 5.75 (-22.09%) | Buy | 2.33 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Apr 2025 | Announcement | VYNE Therapeutics Provides Update on VYN202 Program |
| 20 Mar 2025 | Announcement | VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference |
| 06 Mar 2025 | Announcement | VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update |
| 20 Feb 2025 | Announcement | VYNE Therapeutics to Participate in March Investor Conferences |
| 19 Feb 2025 | Announcement | VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |